PXB-cells® are used for in vitro studies in drug metabolism, enzyme induction/inhibition, safety assessment, transporter evaluation, anti-HBV therapeutics efficacy testing and other studies which require the use of primary human hepatocytes (PHH)
CYP3A activity in PXB-cells
|Measured enzyme||Enzyme activity||Matrix||Processing time||Metabolites|
|CYP3A||Midazolam 1’-hydroxylase||Midazolam (10 µM)||2 hours||1’-hydroxymidazolam|
Measurement by HPLC
Figure shows the comparison of CYP3A activity of commercially sourced donor hepatocytes and PXB-cells® produced with the same source of hepatocytes. PXB-cells® show equivalent to or better CYP3A activity than the original human hepatocytes for 21 days
PXB-cells are delivered by the following plate formats under temperature-controlled conditions (15-25 degrees Celsius).
|24-well Plate:||1.0 x 10^7 cells per plate|
|96-well Plate:||6.5 x 10^6 cells per plate|
|T75 Flask*:||1.6 x 10^7 cells per flask|
* Please note that you can re-plate PXB-cells to your preferred formats from T75 Flasks. We will provide a protocol for the re-plating procedures upon request.
To maintain optimal culture conditions PXB cells should be kept in dHCGM media. We provide dHCGM media (-FBS) in the following formats under frozen conditions:
|dHCGM Medium (- FBS)||100 mL/bottle|
|dHCGM Medium (- FBS)||250 mL/bottle|
* Please note that we can provide a protocol for the preparation of the dHCGM medium upon request.
PXB-cells® were used as a model in vitro system for the prediction of the in vivo metabolism of new drugs of abuse.
A powerful synthetic opioid fentanyl and its analogue acetylfentanyl were studied. Major and minor metabolites were detected with PXB-cells®. The metabolite profiles in PXB-cells® was consistent with the in vivo metabolite profiles of drug users reported previously.
Overall, higher amounts of metabolites were formed in PXB-cells® as compared to another source of commercially available primary human hepatocytes (PHH). Some metabolites were detected only in the medium of PXB-cells®. The difference is attributed to the faster decrease in the activity of metabolizing enzymes in PHH versus PXB-cells® after the start of incubation.
Metabolites identified with PXB-cells
Seeding was performed at PhoenixBio (Japan) facility. 24-well plates were delivered to study facility 2 days later (at Day 0). Drug was added at Day 4 or Day 11 at a final concentration of 10 µM. PXB-cells® were cultured with the drug for 24-48 hours. Media were collected and analyzed by liquid chromatography/ mass spectrometry (LC/MS). The performance of PXB-cells® was compared to the regularly purchased primary human hepatocytes (PHH).